GoAI
Get started
iTonic Holdings Ltd. logo

iTonic Holdings Ltd.

ITOC

NASDAQHealthcareMedical - Specialties

Open in GoAI

Previous close

$0.2917

−$0.0136 · -4.45%

Aug 21, 4:00 PM ET

ITOC company overview

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Sell

Trim exposure — unfavorable risk-reward

Valuation

47

Fair Value

Momentum

26

Weakening

Sentiment

54

Mixed

Risk resilience

13

Extreme Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

iTonic Holdings Ltd., a healthcare solutions firm, specializes in the development and commercialization of software and devices for brachytherapy. Its advanced proprietary treatment planning system centers on radioactive particle implantation, a form of radiotherapy employed in cancer treatment to precisely position radioactive sources within patients, thereby eradicating malignant cells and reducing tumor size. Key among its offerings is FTTPS, a sophisticated treatment planning system engineered for diverse malignant tumors. This system excels at defining the target volume, determining the prescribed dose, establishing safety margins for organs at risk, and formulating a precise dose distribution plan essential for brachytherapy patients. Founded in Beijing, China, in 1998, the company operated as Pheton Holdings Ltd. until its rebranding to iTonic Holdings Ltd. in January 2026. iTonic Holdings Ltd. functions as a subsidiary of ZJW (BVI) LTD.

Industry
Medical - Specialties
Sector
Healthcare
Headquarters
CN
CEO
Jianfei Zhang
Listed since
Sep 5, 2024
Employees
7

Market position

Day range

Current $0.2917

52-week range

Current $0.2917

Open
$0.2895
Previous close
$0.3053
Volume
43.73K
0.03× average
Average volume
1.43M
Average daily volume
Market cap
2.74M USD
Beta
2.76
Market reference 1
50-day average
$0.3024
-3.53% below average
200-day average
$0.3906
-25.31% below average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
5.4M USD
P/E (TTM)
-0.91×
P/B (TTM)
0.8×
P/S (TTM)
5.23×
EV / EBITDA
-1.04×
Earnings yield
-75.50%
Free cash flow yield
-48.05%
Dividend yield
0.00%

Profitability & efficiency

Gross margin
62.59%
Operating margin
-991.71%
Net margin
-974.68%
Return on equity
-83.26%
Return on assets
-56.04%
Return on invested capital
-59.10%

Financial health

Debt / equity
0.02×
Current ratio
8.83×
Altman Z-score
-0.68
Piotroski F-score
2 of 9

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends192%-239%-669%-1099%Gross margin, FY2021: 84.06%Gross margin, FY2022: 82.11%Gross margin, FY2023: 74.90%Gross margin, FY2024: 76.96%Gross margin, FY2025: 62.59%Operating margin, FY2021: 19.65%Operating margin, FY2022: 4.05%Operating margin, FY2023: -48.79%Operating margin, FY2024: -171.86%Operating margin, FY2025: -991.71%Net margin, FY2021: 27.39%Net margin, FY2022: 12.35%Net margin, FY2023: -38.37%Net margin, FY2024: -147.39%Net margin, FY2025: -974.68%FY2021FY2022FY2023FY2024FY2025
Gross margin FY2021 84.06%. Gross margin FY2022 82.11%. Gross margin FY2023 74.90%. Gross margin FY2024 76.96%. Gross margin FY2025 62.59%. Operating margin FY2021 19.65%. Operating margin FY2022 4.05%. Operating margin FY2023 -48.79%. Operating margin FY2024 -171.86%. Operating margin FY2025 -991.71%. Net margin FY2021 27.39%. Net margin FY2022 12.35%. Net margin FY2023 -38.37%. Net margin FY2024 -147.39%. Net margin FY2025 -974.68%.

Income trends

Revenue

523.03K USD+16.70%

Operating income

−5.19M USD-573.40%

Net income

−5.1M USD-671.72%
Income trends across reported periods1.29M USD−1.06M USD−3.42M USD−5.78M USDRevenue, FY2021: 702.78K USDRevenue, FY2022: 679.78K USDRevenue, FY2023: 628.59K USDRevenue, FY2024: 448.2K USDRevenue, FY2025: 523.03K USDOperating income, FY2021: 138.09K USDOperating income, FY2022: 27.52K USDOperating income, FY2023: −306.68K USDOperating income, FY2024: −770.27K USDOperating income, FY2025: −5.19M USDNet income, FY2021: 192.46K USDNet income, FY2022: 83.98K USDNet income, FY2023: −241.22K USDNet income, FY2024: −660.59K USDNet income, FY2025: −5.1M USDFY2021FY2022FY2023FY2024FY2025
Revenue FY2021 702.78K USD. Revenue FY2022 679.78K USD. Revenue FY2023 628.59K USD. Revenue FY2024 448.2K USD. Revenue FY2025 523.03K USD. Operating income FY2021 138.09K USD. Operating income FY2022 27.52K USD. Operating income FY2023 −306.68K USD. Operating income FY2024 −770.27K USD. Operating income FY2025 −5.19M USD. Net income FY2021 192.46K USD. Net income FY2022 83.98K USD. Net income FY2023 −241.22K USD. Net income FY2024 −660.59K USD. Net income FY2025 −5.1M USD.
Metric (USD)FY2025FY2024FY2023FY2022FY2021
Revenue523.03K USD448.2K USD628.59K USD679.78K USD702.78K USD
Cost of goods sold195.68K USD103.26K USD157.76K USD121.63K USD112.03K USD
Gross profit327.35K USD344.94K USD470.83K USD558.15K USD590.74K USD
Research and development459.14K USD93.32K USD84.47K USD73.72K USD81.22K USD
Selling, general, and administrative5.06M USD1.02M USD693.03K USD456.91K USD371.44K USD
Operating expenses5.51M USD1.12M USD777.51K USD530.63K USD452.66K USD
Depreciation and amortization13.31K USD72.43K USD63.13K USD54.08K USD65.95K USD
Operating income−5.19M USD−770.27K USD−306.68K USD27.52K USD138.09K USD
Net income−5.1M USD−660.59K USD−241.22K USD83.98K USD192.46K USD

Company facts updated Aug 24, 2026.

ITOC peers

Amgen Inc. logo

AMGN

Amgen Inc.

$439.33

+1.29%

Gilead Sciences, Inc. logo

GILD

Gilead Sciences, Inc.

$146.12

+1.87%

Vertex Pharmaceuticals Incorporated logo

VRTX

Vertex Pharmaceuticals Incorporated

$548.05

+1.44%

Intuitive Surgical, Inc. logo

ISRG

Intuitive Surgical, Inc.

$378.81

+1.16%

Sanofi logo

SNY

Sanofi

$45.85

+1.55%

Regeneron Pharmaceuticals, Inc. logo

REGN

Regeneron Pharmaceuticals, Inc.

$834.04

+0.90%

Continue in GoAI

Research ITOC

research.disclaimer